GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.25
Bid: 39.35
Ask: 39.50
Change: 2.10 (5.65%)
Spread: 0.15 (0.381%)
Open: 37.95
High: 40.80
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licenses CSD500 to Church & Dwight

2 Apr 2013 07:00

RNS Number : 2832B
Futura Medical PLC
02 April 2013
 



For immediate release

2 April 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

 

Futura licenses CSD500 to Church & Dwight

 

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has signed a licensing deal with Church & Dwight Co Inc, the major US consumer products group whose brands include Trojan® condoms, for the marketing and distribution of CSD500, Futura's novel condom.

 

Trojan® is the number one condom brand in North America and the world's second biggest condom brand by product sales.

 

Under the terms of the agreement, Church & Dwight will hold the rights to manufacture, market and distribute CSD500 in North America and in a number of key European territories.

 

The financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Adrian Huns, Church & Dwight's President of International Consumer Products, commented: "CSD500 is a genuinely novel condom that marks a major breakthrough in condom technology. We look forward to working with Futura on the successful completion of the required approvals necessary ahead of the launch in Europe and North America of a completely new type of condom from a highly trusted brand."

 

James Barder, Futura's Chief Executive, commented: "We are delighted to sign this pivotal agreement with Church & Dwight for the marketing of CSD500 as a Trojan®-branded condom in North America and in key territories in Europe. Trojan® is one of the world's biggest condom brands and the number one brand in North America."

 

"The agreement is in line with the Board's preferred strategy of licensing CSD500 on a geographic basis to condom distributors that hold leading positions in their regions. We continue to negotiate CSD500 rights for other major territories and believe that this strategy will create optimal value for shareholders."

 

 

For further information:

 

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKBDQPBKKNQK
Date   Source Headline
13th Dec 20227:00 amRNSFutura Medical announce milestone year for MED3000
30th Nov 20227:00 amRNSFutura Block Listing Six Monthly Return
30th Nov 20227:00 amRNSTotal Voting Rights
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 202212:25 pmRNSTR-1: Notification of major holdings
4th Oct 20225:31 pmRNSTotal Voting Rights
3rd Oct 20227:00 amRNSApplication to the US FDA for MED3000
16th Sep 20229:57 amRNSPDMR Dealing and Total Voting Rights
13th Sep 20227:00 amRNSFutura Medical Interim Results 2022
1st Sep 20227:00 amRNSNotice of Interim Results
31st Aug 20227:00 amRNSHighly positive FM71 Phase 3 Study Results
12th Jul 20224:41 pmRNSSecond Price Monitoring Extn
12th Jul 20224:35 pmRNSPrice Monitoring Extension
28th Jun 20223:58 pmRNSFutura Medical AGM Results
28th Jun 20227:00 amRNSFutura Medical AGM Statement
7th Jun 20221:33 pmRNSTR-1: Notification of major holdings
1st Jun 20227:00 amRNSNotice of AGM and Availability of Annual Report
31st May 20227:00 amRNSBlock Listing Six Monthly Return
24th May 202211:40 amRNSTR-1: Notification of major holdings
23rd May 202210:35 amRNSAgreement with Cooper Consumer Health - Correction
23rd May 20227:00 amRNSMED3000 Collaboration in EEA, UK & Switzerland
17th May 20223:56 pmRNSTR-1: Notification of major holdings
16th May 20222:51 pmRNSTR-1: Notification of major holdings
13th May 202212:12 pmRNSTR-1: Notification of major holdings
6th May 20224:41 pmRNSSecond Price Monitoring Extn
6th May 20224:35 pmRNSPrice Monitoring Extension
26th Apr 20227:00 amRNSFull Year Results 2021
14th Apr 20223:54 pmRNSFutura Medical Notice of Preliminary Results 2021
11th Apr 20224:28 pmRNSTR-1: Notification of major holdings
1st Apr 20224:58 pmRNSTR-1: Notification of major holdings
23rd Mar 20227:00 amRNSFutura Announces Collaboration with Menarini
2nd Feb 20225:30 pmRNSTR-1:Notification of major holdings
13th Jan 202210:32 amRNSRemuneration of Non-Executive Directors and TVR
20th Dec 20217:00 amRNSUS regulatory and commercial update for MED3000
2nd Dec 202112:02 pmRNSTR-1: Notification of major holdings
30th Nov 20217:00 amRNSBlock Listing Six Monthly Return
30th Nov 20217:00 amRNSFutura Medical plc Total Voting Rights
28th Oct 20217:00 amRNSFutura Medical plc Board Appointment
8th Oct 20217:00 amRNSFutura Medical plc Board Appointment
5th Oct 20214:05 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSInterim Results for Six Months ended 30 June 2021
27th Sep 20217:00 amRNSFutura Announces Collaboration with Labatec Pharma
17th Sep 20217:00 amRNSNotice of Interim Results
15th Sep 20217:00 amRNSFirst Patient visit in MED3000 Confirmatory Study
8th Sep 20213:49 pmRNSTR1: Notification of Major Holdings
31st Aug 20217:00 amRNSFutura Medical Announces Collaboration of MED3000
19th Jul 20217:00 amRNSFDA regulatory and commercial update for MED3000
28th Jun 20211:26 pmRNSResult of AGM
28th Jun 20217:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.